NOVANTA INC. (NOVT): what the price requires

At today's price, NOVANTA INC. (NOVT) is priced for today's economics sustained for ~16.1 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/NOVT

Headline

Field	Value
Ticker	NOVT
Company	NOVANTA INC.
Current price	$150.69/sh
Composition	Precision Manufacturing 19% / Robotics and Automation 32% / Precision Medicine 24% / Advanced Surgery 25%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin needed	20.2%
Operating margin today	9.9%
Margin expansion implied	+10.3pp
Must persist for	16.1y
Multiple paid	54x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 11.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~10.5 years; the models below use their own rates.

How unusual the bet is: high

Reference	Value
vs own history	+0.85σ
cohort percentile (of 225 peers)	92
sustained it ~10 years at this level	15%
implied end-window share	0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	10.68x	3	expensive
Earnings	8.70x	4	expensive
Relative	2.47x	3	expensive
Growth	1.31x	3	expensive

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.0%); the inversion above states its own rate.

Per-Model Detail (n=13)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$38.00	3.97x	yes	FCF base $0.1B, growth 6% (input: historical growth), terminal g 4.0%, WACC 9.0%, 6yr projection
DCF Exit Multiple	Growth	$120.09	1.25x	yes	Exit EV/EBITDA: 38.2x / 40.2x / 42.2x (bear / base = today's held flat / bull), 6yr
Relative Valuation	Relative	$66.26	2.27x	yes	P/E 39.6x (blended: static sector reference 18x + trailing (TTM) 115x), scenarios: 33.1x / 39.6x / 46.1x (bear / base = reference held flat / bull), EV/EBITDA 20.47x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$14.11	10.68x	yes	BV/sh $31.85, ROE (TTM) 4.1%, ke 9.3%
Two-Stage Excess Return	Asset	$9.06	16.63x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$114.78	1.31x	yes	Rev $1.0B, growth 6% (input: historical growth; tapered), Terminal P/S: 5.2x / 6.2x / 7.2x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/E	Relative	—	—	no	—
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$25.61	5.88x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.11B × (1−20%) / WACC 9.0% → EPV (no growth)
Residual Income	Asset	$7.38	20.42x	yes	BV $31.85 + 5yr PV of (ROE (TTM) 4.1% − Kₑ 9.3%) × BV; BV grows 2.7%/yr (excluded from median)
Graham Number	Asset	$31.56	4.77x	yes	√(22.5 × EPS $1.39 × BVPS $31.85) — Graham's conservative floor
EV/EBITDA Relative	Relative	$46.66	3.23x	yes	EBITDA $0.15B × sector EV/EBITDA 12.0x
FCF Yield	Earnings	$20.43	7.38x	yes	FCF $68.5M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$11.97	12.59x	yes	SBC-adj FCF $0.04B (FCF $0.07B − SBC $0.03B) capitalized at Kₑ
Ben Graham Formula	Earnings	$1.16	129.91x	yes	EPS $1.39 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/B	Asset	$6.43	23.44x	yes	BV $31.85 × (ROIC 1.8% / WACC 9.0%) (excluded from median)
P/Sales Sector	Relative	$61.04	2.47x	yes	Revenue $1.00B × sector P/S 2.5x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	$15.03	10.03x	yes	EPS $1.39 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$144.4m
Net debt / NOPAT (after-tax)	-1.86x (net cash)
Net debt / operating income (pre-tax)	-1.49x (net cash)
Share count CAGR (dilution)	3.6%
Burning cash	no

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Novanta builds precision photonics, motion-control, and medical components that get designed into other companies' machines, surgical robots, lasers, automation systems, and medical devices, so its revenue compounds as those platforms scale.
The defining risk is the price: at roughly 56 times earnings the stock trades above what every valuation lens supports, so the buyer is paying for many years of durable high-margin growth to come true rather than for the business as it stands.
The next markers are the $1.2 billion Riverpoint Medical acquisition closing in the third quarter of 2026, which roughly doubles recurring medical consumables revenue, and whether bookings momentum (Q1 2026 book-to-bill of 1.10) holds.

Bull Case

A simple earnings multiple makes Novanta look like it earns almost nothing: an operating margin under 9% on a GAAP basis. That number is an accounting artifact, not the economics. Novanta grows by acquiring specialized component makers, and the amortization of the intangibles it buys runs straight through operating expenses, depressing reported margin while the underlying businesses throw off far more cash. The 10-K is explicit that amortization of purchased intangibles are included in operating expenses in the consolidated statement of operations. What the standard model misses is that the cash margins of these niche, designed-in products are high and durable, because once a Novanta laser or motion stage is qualified into a customer's surgical robot or imaging system, it is expensive and risky to swap out.

The business is a portfolio of small monopolies sold into long product cycles. Across precision manufacturing, robotics and automation, precision medicine, and advanced surgery, Novanta supplies the enabling component rather than the finished machine, which keeps it diversified across end markets while concentrated in things it does better than anyone. The first quarter of 2026 showed the model working on every line: revenue up 10.4% to $257.7 million, bookings up 37% year over year, and a book-to-bill of 1.10, meaning orders outran shipments. Every business delivered double-digit bookings growth, and management raised full-year revenue guidance to $1.04 billion to $1.055 billion despite tariff and freight headwinds.

The strategic move that defines 2026 is the $1.2 billion acquisition of Riverpoint Medical, agreed in June with a further $250 million milestone payment, expected to close in the third quarter. It roughly doubles Novanta's recurring medical consumables revenue to about $300 million and lifts medical exposure toward 60% of the total. That is the deliberate reshaping of the company toward durable, razor-and-blade recurring revenue, the kind that justifies a premium multiple if it holds. The balance sheet supports the ambition, carrying net cash before the deal and a strong acquisition pipeline behind it.

Bear Case

The valuation methods do not disagree about Novanta. They agree, and what they agree on is the bear case: no family of method reaches today's price. Asset value, earnings power, peer multiples, and even a forward-growth model all land below $155 (June 27, 2026). When the conservative lenses and the optimistic one all say the same thing, the honest read is that the price has run ahead of the fundamentals. At roughly 56 times earnings the stock is priced for a long runway of durable, high-margin compounding, and the inverted price embeds an operating margin near 24% sustained for more than fifteen years. That is a demanding bet for any company, and Novanta's GAAP margin today sits well below it; the gap is the optionality the market has already paid for.

The growth engine carries its own fragility, because much of it is bought rather than built. Novanta's strategy depends on a steady supply of acquisitions at sensible prices, financed and integrated well. The Riverpoint deal at $1.2 billion plus a $250 million milestone is a large bite that will move the company from net cash to a leveraged balance sheet, and the value of every acquisition rests on assumptions the filing itself flags as judgment-heavy, including revenue growth rates, customer attrition rates, royalty rates, discount rates and projected future cash flows. A deal that underperforms, or a pipeline that dries up, removes a meaningful part of the growth the multiple assumes.

The demand side is more cyclical than a premium medical multiple suggests. A large part of Novanta's revenue is tied to industrial automation and manufacturing capital spending, which the company benchmarks against the Purchasing Managers' Index, and it sells largely to OEM customers whose own health drives Novanta's orders. The filing is candid about that dependence, warning that the loss of OEM customers experiencing financial or other difficulties could adversely affect results. Layer on the near-term margin pressure from tariffs and freight that management is counting on second-half mitigation to offset, and a stock priced for perfection has little room for a slowdown. The share count has also crept up about 3.6% a year, so per-share growth has to clear the dilution that funds the deals.

Valuation

The blunt fact is that no method reaches the price. Value Novanta on its asset base, on its earnings power, on peer multiples, or on a forward-growth model, and every lens lands below today's $155. The price is a bet beyond what any standard frame supports, and the reported operating margin near 9% understates the cash economics because acquisition amortization flows through operating expense, but even crediting the higher cash margins, the multiple is steep.

What the price is betting is durability and duration. Inverted, today's level implies Novanta sustains an operating margin near 24% for roughly sixteen years, extrapolating its acquire-and-integrate compounding far into the future. At about 56 times earnings, the multiple is the highest-conviction part of the thesis and the most exposed. The right way to read the gap is not that the methods are blind but that the market has already priced the optimistic case in full.

Solvency is sturdy today and about to change shape. Before the Riverpoint acquisition Novanta holds net cash of roughly $144 million, but the $1.2 billion deal plus a $250 million milestone will move it to a leveraged position, so the balance-sheet story pivots from cushion to integration discipline. The share count rising about 3.6% a year is the quieter cost of the strategy, since the deals and equity-based compensation that fund growth also dilute it. The bet the buyer underwrites is that a portfolio of designed-in component franchises, increasingly weighted to recurring medical revenue, compounds at a pace and durability that earns back a 56 times multiple. The business quality is real; the price assumes it stays exceptional for a very long time.

Catalysts

The first quarter of 2026 was broad-based strength. Revenue rose 10.4% to $257.7 million, 3% organically, with bookings up 37% year over year and a book-to-bill of 1.10, and every business delivered double-digit bookings growth. Adjusted EBITDA grew 14% with margin expanding 70 basis points, and management raised full-year revenue guidance to $1.04 billion to $1.055 billion while reaffirming EBITDA and EPS, citing accelerating demand in automation, medical, and AI-related infrastructure markets.

The headline event is the Riverpoint Medical acquisition, announced June 8, 2026, for $1.2 billion in upfront cash plus a $250 million milestone payment due by early 2027, with closing expected in the third quarter subject to regulatory approval. Riverpoint is a leader in minimally invasive surgical consumables, and the deal roughly doubles Novanta's recurring medical consumables revenue to about $300 million while lifting medical exposure toward 60% of total revenue, the clearest step yet in the shift toward durable recurring streams.

Analyst sentiment is uniformly positive but pressed against valuation. The recent ratings cluster at Buy and Strong Buy with price targets near $171 to $173, only modestly above the current price, and the noted concerns are the 56 times multiple and margin timing risk from tariffs until second-half mitigation takes hold. The markers that adjudicate the thesis are the Riverpoint close and early integration, the trajectory of bookings and book-to-bill, and whether the tariff and freight pressure resolves on the schedule management expects.

Peer Cohorts (Per Segment, With Filing Citations)

Automation Enabling Technologies (reported)

MKSI (MKS INC)
(no filing in the citation store)
IPGP (IPG PHOTONICS CORP)
(no filing in the citation store)
COHR (COHERENT CORP.)
(no filing in the citation store)
LITE (Lumentum Holdings Inc.)
(no filing in the citation store)
NVMI (NOVA LTD.)
(no filing in the citation store)
CGNX (Cognex Corporation)
(no filing in the citation store)
ESE (ESCO TECHNOLOGIES INC.)
(no filing in the citation store)

Medical Solutions (reported)

ITGR (INTEGER HOLDINGS CORPORATION)
(no filing in the citation store)
UFPT (UFPT)
(no filing in the citation store)
OSIS (OSI SYSTEMS, INC.)
(no filing in the citation store)

Methodology Note

Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Novanta Q1 2026 earnings release · Novanta Q1 2026 results · Novanta press release, June 2026 · analyst notes, 2026